Almac Discovery licenses anti-angiogenic peptide to Shin Poong in South Korea

Published: 29-Apr-2013 Featured companies: Almac Group
Research & Development

Shin Poong will make undisclosed upfront payment and pay milestones and royalties


Almac Discovery is to license its anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Company for clinical development and marketing in South Korea.

Shin Poong will make an undisclosed upfront payment to Almac and pay milestones and royalties as part of the deal.

The Shin Poong programme in South Korea will run in parallel with Almac Discovery’s own development programme in Europe.

ALM201 is a highly potent anti-angiogenic peptide that is targeted to cells expressing CD44 and acts by inhibiting migration of vascular endothelial cells. The compound has completed preclinical development, has a good toxicology profile and is entering Phase I/II trials in the UK.

Almac Discovery is seeking partners for ALM201 in all other territories.

Featured companies

  • Companies:
  • Shinpoong Pharmaceutical Company
See more

You may also like

Manufacturing

Asynt and Almac team up on bespoke reactor vessels

Read more
The two companies have teamed up design and supply a range of bespoke reactor vessels, highlighting the benefits of utilising Asynt's lab vessels to streamline Almac Sciences' scale-up process

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  3. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
  4. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Relevant companies

See more

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Asynt and Almac team up on bespoke reactor vessels

The two companies have teamed up design and supply a range of bespoke reactor vessels, highlighting the benefits of utilising Asynt's lab vessels to streamline Almac Sciences' scale-up process
Research & Development

Almac expands sequencing capabilities through llumina instrument

Almac has purchased and installed an llumina NovaSeq X Plus instrument in Northern Ireland, which is set to expand its next generation sequencing capabilities for BioPharma partners
Manufacturing

Almac updates software with new content for cancer research

The updates include 16 new gene expression signatures across the Hallmarks of Cancer, improved functionality with online data access and simplified reporting
Research & Development

Almac unveils new Cryogenic Service Solution for advanced therapy trials

Investments in the next generation cold chain solutions at the company’s Durham facility have exceeded $4m
Manufacturing

Almac expands ultra-low temperature offering for ATMPs

The company’s ultra-low temperatures (-20°C to -80°C) offering has been enhanced to offer a tailored experience
Research & Development

Almac and Queen’s University Belfast collaboration passes midpoint

The KTP project has achieved multiple successful outcomes including dissemination through peer-reviewed publication and several conference presentations
Research & Development

Towards the enzymatic synthesis of oligonucleotides: part II

By early 2020, ten oligonucleotide drugs had received US FDA regulatory approval; with many more in the pipeline, it’s only fair to say that this drug class is becoming big business
Subscribe now